Indication

Prevention of thromboembolism in paroxysmal atrial fibrillation

Prevention of thromboembolism in paroxysmal atrial fibrillation refers to prophylactic therapy aimed at reducing the risk of ischemic stroke and systemic arterial embolism in individuals with intermittent, self-terminating atrial fibrillation. Read more about Prevention of thromboembolism in paroxysmal atrial fibrillation

20 drugs 18 manufacturers

Advertisement

Drugs that treat it

Common Prevention of thromboembolism in paroxysmal atrial fibrillation therapies.

Showing 10–18 of 20 drugs

RIVAROXABAN

ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
CAMBER PHARMACE

RIVAROXABAN

ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
MACLEODS PHARMA

RIVAROXABAN

ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
DR.REDDY'S LAB

RIVAROXABAN

ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
ALEMBIC PHARMAC

RIVAROXABAN

ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
SCIEGEN PHARMAC

RIVAROXABAN

ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
EXELAN PHARMACE

RIVAROXABAN

ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
FLORIDA PHARMAC

RIVAROXABAN

ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
TARO/SUN PHARMA

RIVAROXABAN

ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
XLCARE PHARMACE
Filter & compare in the drug finder →Opens the drug finder with Prevention of thromboembolism in paroxysmal atrial fibrillation preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prevention of thromboembolism in paroxysmal atrial fibrillation.

Prevention of thromboembolism in paroxysmal atrial fibrillation refers to prophylactic therapy aimed at reducing the risk of ischemic stroke and systemic arterial embolism in individuals with intermittent, self-terminating atrial fibrillation.

In this cardiovascular condition, recurrent episodes of rapid and disorganized atrial activation impair effective mechanical contractility, causing blood stasis particularly within the left atrial appendage.

This stasis promotes intracardiac thrombus formation, which can dislodge and occlude cerebral or systemic vasculature despite episodes spontaneously resolving within seven days.

Clinical risk stratification guides prophylaxis, as the risk of thromboembolic events in paroxysmal disease remains comparable to that of sustained atrial fibrillation.

Personalize your experience

Follow Prevention of thromboembolism in paroxysmal atrial fibrillation and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it